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Abstract: Viral vectors have been extensively studied due to their great transduction 
efficiency compared to non-viral vectors. These vectors have been used extensively in gene 
therapy, enabling the comprehension of, not only the advantages of these vectors, but also 
the limitations, such as the activation of the immune system after vector administration. 
Moreover, the need to control the target of the vector has led to the development of 
chemical and non-chemical modifications of the vector surface, allowing researchers to 
modify the tropism and biodistribution profile of the vector, leading to the production of 
viral vectors able to target different tissues and organs. This review describes recent  
non-genetic modifications of the surfaces of viral vectors to decrease immune system 
activation and to control tissue targeting. The developments described herein provide 
opportunities for applications of gene therapy to treat acquired disorders and genetic 
diseases and to become useful tools in regenerative medicine. 
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1. Introduction 
Knowledge of viral structures and infection mechanisms has paved the way for a deeper 
understanding of virus interactions with the human body. This information has become extremely 
important as viruses are being used as new vectors, capable of delivering transgenes, in vitro and in vivo, to 
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tissues and cells. Cloning techniques have enabled the modification of different wild type viruses, such 
as adenoviruses, lentiviruses and retroviruses, herpes simplex viruses, and many others, to produce 
viral vectors for gene therapy [1–3]. First, viruses were genetically modified; in particular, genes 
involved in the replication cycle were deleted and/or replaced. These modifications had  
two consequences: (i) larger expression cassettes were inserted into viral genomes, and (ii)  
replication-defective vectors (RDV) and/or conditionally replicating vectors were produced. 
The production of vectors unable to replicate proved to be extremely important in lowering vector 
immunogenicity. A clear example of this reduced immunogenicity is third generation adenoviral 
vectors, also called helper-dependent adenoviral vectors [4]. Most of the genome of these vectors is 
deleted and the resulting vectors are called “gutless-vectors”; hence, this type of adenoviral vector is 
not able to replicate and avoids the chronic toxicity that is typically related to protein expression of 
viral genes [5]. Lentiviral vectors have also been engineered to make these vectors unable to replicate 
once integrated into the host genome [6,7]. 
Modifying the viral genome by deleting genes essential for the replication process represented a 
quantum leap in gene therapy and provided researchers safer and more reliable vectors. Nevertheless, 
these new vectors exhibited limitations when applied to in vivo experimentation protocols. Even 
without viral gene expression, some immunological response was elicited anyway [8]. In fact, the 
interactions between the injected viral vector and molecular receptors responsible for the innate 
immune response [9], such as Toll-like receptors [10–14], are the basis for the acute toxicity observed 
in vivo, which is not related to viral replication but to the mere presence of the vector in the  
organism [8,15]. Therefore, viral vector surfaces were engineered for decreased visibility to the 
immune system. Viruses were masked to reduce interactions with pattern recognition receptors (PPRs) 
that are responsible for the innate immune response [16,17], and this strategy has successfully 
extended transgene expression and lowered anti-vector immune response. 
Moreover, modifications of the virus structure and surface enable the control of viral biodistribution. 
To date, adenoviruses have been the most investigated type of virus due to the natural liver tropism of 
these viruses. Nevertheless, even if liver targeting was desirable, the need to target other organs has led 
to efforts to de-target adenoviral vectors. Liver de-targeting, with consequent controlled re-targeting of 
other tissues has been achieved through viral protein modification [18,19] or the conjugation of vectors 
with peptides and molecular adaptors. 
2. Fighting the Immune Response 
2.1. Polyethylene Glycol and a New Generation of Polymers 
The immune response elicited by viral vectors has limited the use of gene therapy in clinical  
trials [8,20,21]. Pre-existing immunity because of neutralizing antibodies and the interactions of viral 
capsids with PRRs activates the innate immune response [22], limiting the success rate of therapeutic 
approaches. To address this issue, viral vectors have started to be modified to reduce the physical 
interaction of these vectors with immune system elements (Figure 1).  
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Figure 1. Modifying the surfaces of viral vectors for different purposes. Shielding viral 
vectors with polymers and lipidic vesicles typically results in the reduced immunogenicity 
and increased persistence of the vectors in the blood stream. Biomaterials and polymers 
represent a physical barrier that not only prevents neutralization from antibodies but also 
impairs the uptake of the vector by macrophages and antigen presenting cells (APC). 
Polymers can also be linked with peptides and ligands that target a specific receptor, 
changing the vector tropism and allowing efficient re-targeting. 
 
Polyethylene glycol (PEG), a polymer able to increase the half-life of many different drugs and 
reduce their immunogenicity [23], is commonly used to modify the viral surface. PEGylation is able to 
increase transduction efficiency of viral vectors in mice [24] and to prolong the circulation time of 
these vectors [25,26]. More specifically, in murine models, the half-life of systemically injected 
unmodified adenovirus is less than 2 min [27], while the attachment of PEG molecules to these viruses 
reduces viral clearance by a factor of four. Furthermore, adenovirus PEGylation is able to reduce the 
immune response against the vector [28,29]. The production of inflammatory cytokines (IL-6, IL-12, 
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and TNFα) in response to vector administration is greatly affected by vector PEGylation, which is 
actually able to drastically lower the levels of pro-inflammatory cytokines in blood [24]. Moreover, the 
intravenous injection of PEGylated Ad vectors also resulted in significantly fewer Ad-specific 
cytotoxic T lymphocytes in comparison to unmodified Ad- and TH1-mediated responses, which also 
exhibited a marked decrease upon delivery of PEGylated Ad vectors. Interestingly, TH2-mediated 
responses remained unchanged or increased slightly [30]. In addition, PEGylation reduced the 
production of anti-Adenovirus antibodies (anti-Adv Abs) in vivo: Anti-Adv Ig-G and anti-Adv Ig-M 
serum levels of animals treated with PEGylated Ad vectors were greatly reduced in comparison to 
animals treated with naked adenovirus [31]. The PEG coating also helps overcome pre-existing 
immunity, shielding viral vectors from neutralizing antibodies and preserving transduction in vitro [32] 
and in vivo [24]. PEGylation of lentiviral vectors has proved to successfully protect these vectors from 
inactivation by human serum complement [33]. 
To improve the coating system, other polymers have been developed to engineer the surface of the 
viral vectors. Cationic polymers have also been used in combination with PEG, such as  
PEG-poly-L-lysine, which is a multi-block copolymer based on poly(L-lysine) and PEG. This 
interesting compound not only features low toxicity in vitro but this material is also biodegradable 
under physiological conditions: degradation of the copolymer has been reported within 72 h [34]. 
APC, a cationic PEG derivative, protects adenoviruses from neutralizing antibodies (NAbs). In fact, 
exposure to NAbs does not ablate the transduction activity of the APC-coated adenovirus [35] in vitro. 
The conjugation of N-[2-hydroxypropyl] methacrylamide (HPMA) copolymers to the surfaces of 
vectors represents another example of how a polymer coating can mask viral vectors from antibodies. 
An HPMA coating results in an increased half life, lower NAbs binding and decreased interaction with 
complement receptor 1 (CR1) on human erythrocytes [36], which are well known factors for the 
persistence in blood of viral vectors as well as inefficient tissue penetration. Therefore, the protection 
of vectors from NAbs due to an HPMA copolymer coating results in efficient transduction of these 
vectors to Coxsackievirus and adenovirus receptor (CAR)-positive and CAR-negative cells, even in the 
presence of NAbs [37]. Arginine-grafted bioreducible polymers (ABPs) can also be conjugated to the 
surfaces of viral vectors and decrease the production of pro-inflammatory cytokines. ABP conjugation 
to an oncolytic adenovirus significantly lowers IL-6 production in vitro, using RAW 264.7 
macrophages, and in vivo [38]. 
2.2. Lipids Can Hide Vectors 
In addition to polymers, lipids have also been used to improve the safety of viral vectors. Cationic 
liposomes are artificially generated lipid vesicles frequently used for DNA or drug delivery and have 
been widely used in fundamental molecular biology and for gene therapy as a non-viral vector. Small 
unilamellar vesicles (SUV) can be complexed to adenoviruses with a simple mixing reaction (30 min 
at 37 °C) [39]. In mice injected with Adenovirus/SUV complexes, the levels of anti-adenoviral  
vector antibodies are 6.5-fold lower than those from mice injected with the naked vector; thus, these 
polymer-coated vectors are less immunogenic. Moreover, SUV-conjugated Ad vectors are less 
susceptible to inactivation by neutralizing antibodies, allowing the successful re-administration of the 
adenoviral vector to mice [39]. 
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Lipidic envelopes can also be used as shields for viral vectors to lower the immune response. 
DOTAP:CHOL and DOPE:CHEMS are, respectively, cationic and anionic lipid envelopes able to 
decrease the production of NAbs after intra-venous injection [40]. 
In conclusion, following the example of PEG, new generations of compounds and polymers have 
been developed to bind to capsid proteins and act as physical barriers to interactions between the 
immune system elements and viral proteins, resulting in less immunogenic vectors for gene therapy. 
3. Controlling the Target 
More than a decade ago, CAR was identified as the primary cell surface component to interact with 
these adenoviruses and the key for the entry of adenovirus 2 and 5 serotypes into permissive cells [41]. 
Along with alpha V integrin, these molecules were believed to be responsible for the observed liver 
tropism of adenoviral vectors in vivo. Furthermore, other viruses have been studied to understand the 
mechanisms behind their tropisms: vesicular stomatitis virus (VSV) shows neuronal tropisms due to 
glycoprotein (G) and matrix protein (M) [42]; nevertheless, this virus is also able to transduce into a 
great variety of tissues by binding the LDL receptor [43]. Similarly, human immunodeficiency virus 
(HIV) uses chemokine receptor CCR5 on lymphocytes for its entry into cells [44]. Even if the presence 
of a receptor on target cells was the only factor required for the entry of viruses, there has been an 
interesting exception to this rule: adenoviruses. 
Once the elements on the adenovirus surface responsible for cell entry (fiber and an RGD motif in 
the penton base) were identified, several research groups began to modify capsid proteins to avoid 
liver transduction and to achieve the successful re-targeting of adenoviral vectors. Interestingly, 
adenoviruses with mutated fibers and an RGD motif deletion continued to show high liver transduction 
and liver accumulation [45]. These findings suggested that other factors were most likely involved in 
the tropism of adenoviral vectors, and later, coagulation factor X (FX) was identified as the key 
element for liver targeting of adenoviral vectors [46]. The idea that other elements, which do not 
belong to the structure of the virus, could affect viral tropism has been very attractive to researchers 
and a great number of strategies have been developed to modify the surface of viral vectors  
for re-targeting. 
In this review, we have already discussed PEGylation and its importance in preventing  
capsid-mediated toxicity. Moreover, we would like to highlight that PEGylation may also influence 
cell entry and tissue targeting. In fact, depending on the size of the PEG molecules, the surface of the 
viruses can change drastically and alterations in the transduction of cells in vitro and in vivo are 
commonly observed. In addition, anatomical and physiological species differences should be taken 
into account when using PEGylated vectors: in rodents PEGylated vectors show similar transduction in 
comparison to unmodified viruses, however, in non-human primates, PEGylation causes a decrease  
in transduction [47]. 
The decreased transduction observed in different in vitro and in vivo experiments is not only related 
to the increased size of the modified vectors but also to the non-specific nature of the PEGylation 
process because controlling the site of attachment is not possible. PEG molecules can cover areas of 
the capsid that are necessary for cell entry. Hence, novel strategies have been developed to control the 
attachment of PEG molecules on the surface of adenoviruses. An interesting example is represented by 
Biomedicines 2013, 1 8 
 
 
the use of the FX as a PEG “guide”. In fact, due to the specific interaction between FX and hexon 
protein, FX can be used as an adapter to avoid uncontrolled coating. Specifically, FX is first 
PEGylated and then mixed with naked adenovirus [48]. 
3.1. Passive Re-Targeting with Lipids 
High uptake of adenoviral vectors by the liver could be observed as an obstacle to the development 
of therapies. Additionally, avoiding excessive retention by the liver is an important reason to de-target 
viral vectors. The construction of lipidic envelopes constitutes a strategy to engineer viral surfaces to 
control the biological properties of these surfaces. In fact, differences in the surface potential could 
lead to drastic changes in transduction. Positive or negative surface envelopes seem to block the 
interaction with the CAR receptor. Nevertheless, cationic envelopes are still able to enhance vector 
uptake by binding the enveloped virus to the negatively charged cell membrane, but the presence of the 
envelope disrupts normal endosomal trafficking and leads to no transgene expression in vitro [39]. 
However, cationic non-pH sensitive envelopes (DOTAP:CHOL) and anionic pH-sensitive envelopes 
(DOPE:CHEMS) can be used in vivo to avoid liver uptake because, when injected intravenous (i.v.), 
these enveloped vectors show reduced liver accumulation [40]. Nano-engineering artificial envelopes 
around adenoviral vectors have also been reported to result in an enhanced ability to penetrate into 
tumor spheroid cell culture [39]. 
3.2. Passive Re-Targeting with Polymers and Magnetic Particles 
The polymer coating of viral particles can also lead to liver de-targeting. In fact, PEGylation with 
either low or high molecular weight PEG has been reported to reduce transduction of cells in vitro [49–51]. 
Interestingly, even if PEGylation impairs in vitro activity, in vivo experiments show that different sizes 
of PEG can affect liver transduction in different ways and allow liver de-targeting. In fact, low 
molecular weight PEG does not significantly change the biodistribution profile of PEGylated adenoviral 
vectors, which continue to accumulate in the liver and to transduce hepatocytes [50]. However, high 
molecular weight PEG can reduce liver transduction [49]. Another study showed that coating the 
vector with HPMA polymer results in a 100-fold increase in hepatic transgene expression, resulting in 
lower liver toxicity and increased vector bioavailability [52]. Covalent attachment of chitosan to 
adenoviral capsids via a thioether linkage between chitosan modified with 2-iminothiolane and Ad 
cross-linked with N-[c-maleimidobutyryloxy]succinimide ester (GMBS) represents an alternative 
method for vector coating, allowing transduction into corneal epithelial cells in vitro [53]. 
De-targeting can also be achieved using cationic polyamidoamine (PAMAM) cascade dendrimers 
that feature high levels of transfection into a wide variety of cellular types in cell culture [54]. 
Dendrimers represent a novel class of polymers characterized by regular dendritic branching and radial 
symmetry. A recent study showed that coating Ad with cation PAMAM dendrimers can successfully 
re-target viral vectors. In vitro assays showed increased transduction of cells with low CAR levels and 
also a slight increase of transduction into hepatic cells (high CAR levels). Nevertheless, excessive 
coating led to a decrease in transduction levels into cells [55]. In addition, the PAMAM coating also 
showed increased resistance to NAbs. 
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An interesting approach is represented by the attachment of superparamagnetic nanoparticles 
(MNPs) to the surfaces of viral vectors. Cell cultures can be incubated with MNPs/vector complexes 
formed by electrostatic and hydrophobic interactions and positioned above an external magnetic field 
gradient generated by specific permanent magnets. MPNs have been used in combination with 
different viral vectors, such as adenoviral vectors [56], adeno-associated viral vectors [57], and 
lentiviral vectors [57]. Magnetic beads can be a useful tool for in vitro or ex vivo cell engineering 
because the binding of MNPs possibly results in a lower vector dose for optimal transgene delivery 
while improving transduction efficiency [58]. 
3.3. Active Re-Targeting with Peptide Motifs 
Using peptides to actively re-target viral vectors has proven to be a noteworthy approach.  
New high-throughput screening methods discovered tumor-targeting peptides that have the ability to 
accumulate in tumors, and for this reason, these peptides may be used to drive viral vectors towards the 
tumor site. These tumor-homing peptides have been used in different approaches. 
For example, peptide-phage library screening revealed novel ligands that are associated with tumor 
neovascularization, such as the CGKRK peptide. This ligand accumulates on the surface of tumor 
vessels after intravenous injection, suggesting this peptide is a potential active targeting ligand [59]. 
Hence, the CGKRK peptide has been tested for its ability to re-target PEGylated adenoviral vectors: 
PEG molecules, with a maleimide functional group, are attached to the surface of adenoviral vectors; 
then, a reaction between the SH group of the CGKRK peptide and the functional group of PEG causes 
covalent binding of the tumor homing peptide to the PEGylated vector [60]. In vivo experiments show 
that after i.v. administration of Ad-PEG-CGKRK into B16BL6-bearing mice, the amount of  
Ad-PEG-CGKRK in tumor tissue was, respectively, 60-fold and 3-fold higher than that of unmodified 
Ad and Ad-PEG. In addition, the amount of Ad-PEG-CGKRK in liver tissue was 15-fold less than that 
of unmodified Ad, but almost the same as Ad-PEG [61]. Interestingly, tumor-homing peptides can be 
employed not only in therapeutic approaches but also in viral vector-based imaging systems. An 
example of this is the construction of an adenoviral vector carrying the herpes simplex virus 1 
thymidine kinase (HSV1-tk), an enzyme able to metabolize substrates labeled with positron emitter 
radioisotopes, such as 18F and 124I, that can be visualized by a Positron emission tomography (PET) 
imaging system. This viral vector has been coated with RGD peptides using PEG linkers. RGD 
peptides are well known for binding integrins, such as αvβ3, which are usually overexpressed on tumor 
cells and the neovasculature of tumors of various origins. This engineered adenoviral vector has shown 
decreased liver uptake and increased tumor accumulation when visualized by a PET imaging system  
in vivo [62]. 
In addition to enhancing tumor tropism, RGD peptides have also been used for increasing 
transduction efficiency in vitro. In fact, another study focused on the ability of cyclic-RGD peptides to 
enhance adenoviral transduction into human mesenchymal stem cells (hMSCs). More specifically, 
hMSCs were incubated with a GFP-expressing adenovirus and cyclic-RGD peptides. Fluorescence 
analysis of this system showed a 4.9-fold increase in gene expression in comparison to hMSCs 
incubated with the adenovirus alone [63]. 
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3.4. Active Re-Targeting with Natural Ligands 
In addition to small peptides motifs, real ligands, such as EFG and FGF, the receptors of which are 
commonly upregulated on the surface of different tumors, have also been employed for tumor  
targeting [64]. Ligands can be attached to different reactive polymers and the resulting complexes can 
be used for viral vector coating. Berg et al. reported that EGFR-targeted Ad is able to transduce  
EGFR-positive cells in a specific and CAR-independent way. The polymer poly(2-(dimethylamino)ethyl 
methacrylate) (pDMAEMA)-avidin has been mixed with biotin-EGF and used for Ad coating in 
combination with pDMAEMA-PEG complexes for the better charge shielding of Ad. As reported,  
Ad-pDMAEMA-EGF-PEG successfully transduces EGFR positive cells and CAR-deficient cells. 
Interestingly, these coated viruses also showed that the light treatment of target cells could enhance 
transduction efficiency due to photochemical internalization of Ad complexes [65]. Seymour et al. 
used a similar approach. Murine EGF was conjugated to reactive HPMA copolymer and the  
mEGF-HPMA was used to coat the Ad; this polymer-coated virus showed improved and selective 
transduction into EGFR positive cells. The in vivo performance of an oncolytic adenovirus coated  
with mEGF-HPMA was illustrated in a murine xenograft model. Mice that were administered  
mEGF-HPMA-Ad had significantly longer median survival compared with mice that received 
untargeted HPMA-Ad [66]. 
Dendrimers can also function as molecular adaptors to bind targeting peptides on the surface of 
vectors. An EGF mimetic peptide (GE11) has been used to enhance transduction of EGFR 
overexpressing tumors, which is known to be overexpressed on approximately 60% of solid tumors. 
The peptide has been linked to the PAMAM dendrimer polymer through a PEG linker and then the 
adenoviral vector has been coated with the PAMAM-PEG-GE11 complex. Transgene expression 
analysis revealed a 2.3-fold increase compared to a control vector (Ad-PAMAM-PEG-Cys) in vitro [55]. A 
PAMAM coating has also been employed to engineer the surface of baculovirus-based vectors, which 
have been used to transduce the VEGF gene to stem cells [67]. In vivo imaging tests confirmed the role 
of PAMAM in vector re-targeting using an adenovirus encoding NIS, a theranostic agent used for the 
noninvasive imaging of biodistribution and transduction efficiency by 123I scintigraphy. Imaging data 
revealed that viral evasion of liver accumulation led to reduced liver toxicity [68]. 
EGFR targeting is not the only example of receptor targeting of vectors. Folate receptor is 
expressed by different types of carcinomas, such as ovarian cancer [69] and nasopharyngeal and 
laryngeal carcinoma [70]. A simple reaction between naked viral vectors and reactive folate is enough 
to produce a folate-coated viral vector. This approach has been tested for moloney leukemia virus and 
adenovirus producing positive results with regards to re-targeting. In fact, after folate conjugation, both 
vectors were able to transduce human KB cells [71]. 
Another recent study investigated the effect of a chitosan-PEG-folate complex coating upon the 
biodistribution of an oncolytic adenovirus. As expected, the additional presence of PEG increased the 
blood circulation time of oncolytic Ad-nanocomplexes, showing a remarkable 378-fold decrease in 
liver uptake compared to naked Ad. In addition, this coating strategy resulted in a 2007-fold increase 
in the tumor-to-liver ratio of oncolytic Ad, leading to a better anti-tumor response and lower hepatic 
toxicity after i.v. administration [72]. 
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Ligand-based re-targeting has also been possible using the fibroblastic growth factor 2 (FGF2) 
molecule to target FGFR positive malignant cells. The adenovirus vector has been directly conjugated 
to FGF2 and the system proved to be effective in vivo using either CAR positive or CAR negative cell 
lines in murine xenograft tumor models [73]. As reported for other ligand molecules, FGF2 can also be 
attached to reactive polymers, such as PEG [74] or pHPMA [75], resulting in increased blood circulation. 
Interestingly, FGF2 retargeted Ad showed increased and unexpected binding to murine blood  
cells [75]. This evidence suggests that ligands should always be selected carefully and non-specific 
interactions may occur in vivo, leading to reduced availability of injected vectors. 
4. Conclusions 
Many different and interesting strategies have been described in this review. In sum, these new 
methodologies are a clear sign that gene therapy with viral vectors has been evolving rapidly over the 
past few years and has taken advantage of new technologies. We can deduce that the viral vector 
engineering field increasingly depends on research in other related and unrelated fields, especially 
immunology, biomaterials, and nanoparticles research. 
Since the first use of PEG, many other polymers have been individuated as alternative biomaterials 
to coat vectors, leading to a great variety of possibilities to engineer the surfaces of viral vectors and to 
offer flexibility to research groups. Polymers conjugated to viral vectors have proven to represent an 
excellent strategy to hide the vector from the immune system, resulting in lower immunogenicity and 
reduced risks for human experimentation. In addition, the polymer coating can cause liver de-targeting, 
avoiding the depletion and fast clearance of vectors from blood. Furthermore, these polymers have also 
been used as adaptors to bind small molecules to vectors. Peptides and ligands have made possible the 
active re-targeting of viral vectors to other tissues or tumors. 
With further progress in biomaterials and nanoparticle science, a great number of new approaches 
are expected to emerge that improve old gene delivery systems and create new ones. 
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